

Clinical outcome and fusion rates after surgery with TM Ardis interbody fusion system

Submission date 19/12/2013	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 27/01/2014	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 14/04/2021	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Trabecular Metal™ is extensively used in many orthopaedic implants manufactured by the company Zimmer Spine (in hip replacements and knee replacements among other devices). Zimmer also has a wide range of Trabecular Metal™ spinal interbody fusion cages for the cervical as well as the lumbar spine. Manufactured entirely from Trabecular Metal™ material, the TM Ardis interbody device is intended for fusion at one or two connecting levels in the spine. This study is a post-market clinical follow-up study. The data collected from this study will serve the purpose of confirming the safety and performance of the TM Ardis implant.

Who can participate?

Patients suffering from degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis who have six months failed conservative treatment.

What does the study involve?

Over a period of two years participants will be followed on a regular basis (3, 6, 12 and 24 months) to assess clinical outcomes and radiological parameters. Patients will be asked to answer some quality of life questionnaires as well as pain scales.

What are the possible benefits and risks of participating?

There will be no supplementary benefits than the one patients receive when having such a surgery.

Where is the study run from?

Six European centers will be involved in five countries (Spain, Germany, Sweden, Belgium, United Kingdom). For UK the hospital involved is Frimley Park NHS Foundation Trust.

When is the study starting and how long is it expected to run for?

There will be 1 year for recruitment and two years follow up. It is anticipated that recruitment in UK will begin by March 2014.

Who is funding the study?

Zimmer Spine (France)

Who is the main contact?
Dr Mark Thomas, FRCS in Frimley NHS Hospital

Contact information

Type(s)
Scientific

Contact name
Dr Mark Thomas

Contact details
Frimley Park NHS Foundation Trust
Portsmouth Road
Frimley
United Kingdom
GU16 7UJ

Additional identifiers

ClinicalTrials.gov (NCT)
NCT02429908

Protocol serial number
CME2013-01S

Study information

Scientific Title
A prospective, multi-center, post-market surveillance study to assess the clinical efficacy and fusion rates of the Zimmer® Ardis Interbody Fusion System

Acronym
TMARDIS

Study objectives
The goal of this study is to demonstrate that implant is effective in reducing patient disability, which will be assessed with the Oswestry Disability Index (ODI) questionnaire.

Ethics approval required
Old ethics approval format

Ethics approval(s)

1. Regional Ethical Review Board in Gothenburg (Regionala etikprövningsnämnden i Göteborg), Sweden, 12/11/2013
2. Ethics Committee of the State Medical Association Brandenburg (Landesärztekammer Brandenburg), Germany, 07/08/2013
3. NHS Research Ethics Committees, UK - submission pending

Study design

Multi-center prospective open post-market surveillance study

Primary study design

Observational

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis

Interventions

Lumbar surgery: Over a period of two years participants will be followed on a regular basis (3, 6, 12 and 24 months) to assess clinical outcomes and radiological parameters. Patients will be asked to answer to quality of life questionnaires as well as pain scales.

Intervention Type

Device

Phase

Phase IV

Primary outcome(s)

Improvement in patient's Oswestry Disability Index (ODI) score after TM Ardis cage insertion. A 15-point ODI improvement is expected to claim success of the criterion. Measure will be assessed preoperatively at 3, 6, 12 and 24 months.

Key secondary outcome(s)

The occurrence of implant-related complications defined as subsidence, breakage, migration and retrieval. Except radiological tests, the outcomes will be measured with questionnaires in native language preoperatively at 3, 6, 12 and 24 months. Radiological parameters calculation will be assessed by an external company.

Completion date

31/05/2018

Eligibility

Key inclusion criteria

1. Age 18 years or over
2. Degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies.
3. ODI over or equal to 40/100
4. Back pain over or equal to 4/10
5. Mono segmental lumbosacral disease fulfilling the prior conditions: only one level between L2 and S1
6. Skeletally mature patients
7. Six months failed conservative treatment

8. Gave written consent to take part in the study by signing patient informed consent form
9. Physically and mentally able to comply with the protocol, including ability to read and complete required forms and adhere to the follow-up requirements of the protocol

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Prior surgical procedure at the index level using the desired operative approach
2. Severe degenerative lesions at more than one level of the lumbosacral spine
3. Morbid obesity (BMI \geq 40)
4. Active local infection in or near the operative region
5. Active systemic infection and/or disease
6. Severe osteoporosis or insufficient bone density, which in the medical opinion of the physician precludes surgery or contraindicates instrumentation
7. Known or suspected sensitivity to the implant materials
8. Endocrine or metabolic disorders known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, hypothyroidism)
9. Systemic disease that requires the chronic administration of nonsteroidal anti-inflammatory or steroidal drugs
10. Significant mental disorder or condition that could compromise the patient's ability to remember and comply with preoperative and postoperative instructions (e.g. current treatment for a psychiatric/psychosocial disorder, senile dementia, Alzheimer's disease, traumatic head injury)
11. Neuromuscular disorder that would engender unacceptable risk of instability, implant fixation failure, or complications in postoperative care
12. Pregnant
13. Unwilling to follow postoperative instructions, in particular with respect to athletic or occupational activities
14. Current vertebral metastatic tumors
15. Symptomatic cardiac disease
16. Severe congenital or acquired vertebral deformities

Date of first enrolment

03/03/2014

Date of final enrolment

29/10/2015

Locations

Countries of recruitment

United Kingdom

England

Belgium

Germany

Spain

Sweden

Study participating centre

Frimley Park NHS Foundation Trust

Frimley

United Kingdom

GU167UJ

Sponsor information

Organisation

Zimmer Spine (France)

ROR

<https://ror.org/029j6tp05>

Funder(s)

Funder type

Industry

Funder Name

Zimmer Spine (France)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration